Literature DB >> 15687956

[Analysis of variation in delivered dose in diagnostic and therapeutic cerebral angiography].

D Ben Salem1, D Martin, L S Aho, P M Walker, A Lalande, F Brunotte, D Krause, F Ricolfi.   

Abstract

OBJECTIVES: Analysis of dose-area product (DAP) in cerebral angiography, according to the type of pathology and technique used.
MATERIALS AND METHODS: Use of dosimetric and clinical data resulting from 84 diagnostic cerebral angiograms and 32 cerebral embolizations.
RESULTS: The diagnostic angiography data were divided into three categories: A/ When a secondarily embolized aneurysm was diagnosed: n=17. B/ When the final diagnosis was an arteriovenous malformation (AVM): n=10. C/ In the case where the diagnosis was neither AVM, nor aneurysm to embolize: n=57. The cerebral embolizations were classified in two sub-groups: K/ When the embolization immediately followed the diagnostic angiogram: n=15. L/ When the embolization of the aneurysm took place 24 to 48H after the angiography: n=17. The mean DAP of group B containing the AVM is higher than mean DAP values in groups A and C, because of the increased cinegraphic time. There is a strong correlation between the duration of the fluoroscopy and the DAP (n=116; r=0.931; p<0.0001). Addition of runs in the group L contributes to the augmentation of the exposure time (significant difference in time: p=0.0054) and thus with the fact that DAP L>DAPK.
CONCLUSION: Radiation dose during diagnostic cerebral angiography is increased in the presence of AVM. DAP of embolizations are higher when diagnostic and therapeutic phases are separated in time.

Entities:  

Mesh:

Year:  2004        PMID: 15687956     DOI: 10.1016/s0150-9861(04)97020-4

Source DB:  PubMed          Journal:  J Neuroradiol        ISSN: 0150-9861            Impact factor:   3.447


  1 in total

1.  How to set up and apply reference levels in fluoroscopy at a national level.

Authors:  A Aroua; H Rickli; J-C Stauffer; P Schnyder; P R Trueb; J-F Valley; P Vock; F R Verdun
Journal:  Eur Radiol       Date:  2006-10-27       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.